Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD)

Trial Profile

Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms COLUMBUS-AMD
  • Sponsors Bioeq
  • Most Recent Events

    • 06 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 18 Nov 2015 According to a Formycon AG media release, the company is planning to initiate the phase III study in the third quarter of 2015 for which it received preliminary guidance from the European Medicines Agency (EMA).
    • 18 Nov 2015 According to a Formycon AG media release, planned initiation date changed to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top